Johnson & Johnson halts development of RSV vaccine in midst of late-stage clinical trials

Janssen, the pharmaceutical division of the Johnson & Johnson companies, announced Wednesday that it will scrap development of a vaccine for respiratory syncytial virus, or RSV, in adults.The company was in late-stage clinical trials of a vaccine to prevent lower respiratory tract disease in adults over the age of 60 with RSV.

Read at www.cnn.com